AxoGen stock
AXGNNASDAQAxoGen, Inc., HealthcareISIN US05463X1063
47Score 47 out of 100, Weak
Price and trend
81 / 100
Price history
+130% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 37% above it.
Since September 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 78).
The price is 5.5% below its 52-week high. Largest decline in 20 years: 94% (July 2018 to November 2023).
Chart figures for advanced users
- SMA 50$43.09
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$40.42
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)78
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$23.55
- The lowest closing price of the last twelve months.
- Resistance$58.63
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- AxoGen, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $3.31B, is number 32 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $225.21M (up 20.2% year on year) and a loss of $15.7M.
- For fiscal 2026, analysts expect on average revenue of $290.36M (up 28.9%) and adjusted earnings per share of $0.55 (up 91.1%).
Show more
- MEQIRI Score 47 out of 100 (Weak): rank 412 of 702 in Healthcare, median 53.
- Our model puts fair value at $22.97, with the price 141% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $348.07M, financial debt $19.47M.Stability 56
- Analysts expect strong earnings growthUp 27.5% a year through 2028 (estimates from 6 analysts).Growth 66
Weaknesses
- Above fair valuePrice 141% above the fair value of $22.97.Valuation 25
- Loss-makingLoss of $31.92M over the last 12 months.Fundamentals 17
- DilutionShare count up 15% since 2020.Capital allocation 18
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 46 to 47.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- price up very strongly over the past year
- high price swings
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $15.32 and expensive above $45.95 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $18.65, at 7.8% it would be $29.50.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 24.3% on the twelve months before. Revenue has grown strongly since 2006, at around 48% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 74%, operating −3%, net −7%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 23 Feb 2027in 102 days
- Last reported
- 28 Oct 2026EPS reported $0.21 (expected $0.13)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 22.1% since 15 Oct 2026.
- Earnings per share
- $0.55+22.1%
- Revenue
- $290.36M+2.5%
- Earnings per share
- $0.71+3.0%
- Revenue
- $372.65M+4.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +32.5%AxoGen raised its full-year 2026 guidance to at least $290 million in revenue and at least 29% growth, up from a lower expectation that excluded the BioCircuit contribution.
“We now expect full-year 2026 revenue growth of at least 29% or revenue of at least $290 million, including at least $7 million of revenue from BioCircuit. Excluding BioCircuit, we expect organic revenue to be at least $283 million, representing organic growth of at least 26%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $4.66M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Tyndall Joseph A.Sale
2 Sept 2026, Board
- Shares
- 3,500
- Price
- $49.70
- Value
- $173,940
- Wendell Amy McBrideSale
11 Aug 2026, Board
- Shares
- 13,353
- Price
- $48.42
- Value
- $646,592
- Began Marc ASale
10 Aug 2026, EVP & General Counsel
- Shares
- 67,500
- Price
- $47.35
- Value
- $3.2M
Show 1 more
- Weiler Kathy JohnsonSale
7 Aug 2026, Board
- Shares
- 14,150
- Price
- $45.30
- Value
- $640,967
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at AxoGen
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- HaemoneticsHAE $5.59B73
- LivaNovaLIVN $4.97B66
- Integer HoldingsITGR $4.3B56
- AmbuAMBU-B.CO $3.4B71
- TransMedics GroupTMDX $3.2B57
- iRhythm TechnologiesIRTC $3.1B30
- GN Store NordGN.CO $2.63B55
- NeogenNEOG $2.44B41
ETFs that hold AxoGen
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.96% | 0.49% | €318.64M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.23% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.22% | 0.40% | €813.42M |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.09% | 0.30% | €4.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.09% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.09% | 0.30% | €2.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.5B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.03% | 0.45% | €1.54B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 4 Sep 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.